{"id":37117,"date":"2026-06-26T06:02:59","date_gmt":"2026-06-26T00:32:59","guid":{"rendered":"https:\/\/atsixty.com\/?p=37117"},"modified":"2026-06-26T06:03:36","modified_gmt":"2026-06-26T00:33:36","slug":"gynaecological-malignancies","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/","title":{"rendered":"Gynaecological Malignancies"},"content":{"rendered":"\n\n\n\n\nMorning Rounds \u00b7 Gynaecological Malignancies<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#gyn07 *,#gyn07 *::before,#gyn07 *::after{box-sizing:border-box;margin:0;padding:0}\n#gyn07{\n --ob:#4B3A6E;\n --ob-light:#5F4D85;\n --ob-pale:#EFE9F5;\n --ob-dark:#362952;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#241B36;--ink-mid:#4A3D63;--ink-soft:#8A7FA0;\n --line:#E0D8EC;--cream:#F8F6FB;--warm:#FCFBFD;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#gyn07 .mr-header{background:var(--ob);color:#F3EFFA;padding:34px 24px 28px;text-align:center}\n#gyn07 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#gyn07 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#gyn07 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#gyn07 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#gyn07 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#gyn07 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n#gyn07 .mr-sentinel{height:1px}\n#gyn07 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(36,27,54,0.08);padding:9px 16px;display:none}\n#gyn07 .mr-progress.visible{display:block}\n#gyn07 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#gyn07 .mr-pips{display:flex;align-items:center;justify-content:center}\n#gyn07 .mr-pip-wrap{display:flex;align-items:center}\n#gyn07 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#gyn07 .mr-pip-line.done{background:var(--ob)}\n#gyn07 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#gyn07 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#gyn07 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#gyn07 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#gyn07 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ob);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(36,27,54,0.05)}\n#gyn07 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#gyn07 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ob);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#gyn07 .mr-meta{flex:1}\n#gyn07 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob);opacity:0.75;margin-bottom:5px}\n#gyn07 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#gyn07 .mr-stem strong{font-weight:600}\n#gyn07 .mr-stem em{font-style:italic}\n#gyn07 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#gyn07 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#gyn07 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#gyn07 .mr-opt:hover{border-color:var(--ob);background:var(--ob-pale)}\n#gyn07 .mr-opt.locked{cursor:default}\n#gyn07 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#gyn07 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#gyn07 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#gyn07 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#gyn07 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#gyn07 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#gyn07 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#gyn07 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#gyn07 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#gyn07 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#gyn07 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#gyn07 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#gyn07 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#gyn07 .mr-exp{display:none;border-top:1px solid #d4c5e8;background:linear-gradient(180deg,#ece4f6 0%,#f4eff9 100%);padding:13px 20px 15px}\n#gyn07 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:#3F2D60;margin-bottom:6px}\n#gyn07 .mr-exp-text{font-size:0.86rem;color:#2A1F40;line-height:1.68}\n#gyn07 .mr-exp-text strong{font-weight:600}\n#gyn07 .mr-exp-text em{font-style:italic}\n#gyn07 .mr-img-wrap{margin-top:14px;background:var(--warm);border:1px solid var(--line);border-radius:8px;padding:14px;text-align:center}\n#gyn07 .mr-img-wrap figcaption{font-size:0.73rem;color:var(--ink-soft);font-style:italic;margin-top:8px;line-height:1.4}\n#gyn07 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#gyn07 .mr-btn{background:var(--ob);color:#F3EFFA;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(75,58,110,0.28)}\n#gyn07 .mr-btn:hover{background:var(--ob-dark)}\n#gyn07 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ob);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(36,27,54,0.08);overflow:hidden}\n#gyn07 .mr-score-in{padding:28px 24px;text-align:center}\n#gyn07 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#gyn07 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ob) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#gyn07 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#gyn07 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#gyn07 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ob)}\n#gyn07 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#gyn07 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#gyn07 .mr-score-net{font-size:0.9rem;color:var(--ob);font-weight:600;margin-bottom:4px}\n#gyn07 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#gyn07 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#gyn07 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#gyn07 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#gyn07 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#gyn07 .mr-band-s{background:var(--ob-pale);color:var(--ob)}\n#gyn07 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ob);color:var(--ob);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#gyn07 .mr-retry:hover{background:var(--ob);color:#F3EFFA}\n@media(max-width:480px){#gyn07 .mr-title{font-size:1.4rem}#gyn07 .mr-num{font-size:1.7rem}#gyn07 .mr-stem{font-size:0.9rem}#gyn07 .mr-opt-text{font-size:0.86rem}}\n<\/style>\n\n<div id=\"gyn07\">\n\n <div class=\"mr-header\">\n <div class=\"mr-eyebrow\">Morning Rounds · Gynaecology Series · Round 07<\/div>\n <div class=\"mr-title\">\n Gynaecological<br><em>Malignancies<\/em>\n <\/div>\n <div class=\"mr-subtitle\">Five cases · Cervical, endometrial & ovarian cancer · risk, screening & staging · Trust your instinct<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Cases<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"gyn07-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"gyn07-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"gyn07-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"gyn07-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"gyn07-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"gyn07-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Round Complete<\/div>\n <div class=\"mr-ring\" id=\"gyn07-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"gyn07-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"gyn07-net\"><\/div>\n <div class=\"mr-verdict\" id=\"gyn07-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"gyn07-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"gyn07-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"gyn07-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"gyn07-retry\">↻ New Round<\/button>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div><!-- end #gyn07 -->\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'gyn07';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [\n\n {\n id: 1,\n tag: 'Cervical Cancer — HPV Risk Stratification',\n stem: 'A patient asks why HPV vaccination targets specific viral types rather than all HPV strains. Which HPV types are most strongly linked to cervical cancer, and how do they differ from the types most associated with genital warts?',\n correct: 'HPV types 16 and 18 cause the large majority of cervical cancers and are classified as high-risk oncogenic types, whereas types 6 and 11 are low-risk types primarily responsible for genital warts rather than malignant transformation; vaccines target the high-risk oncogenic types driving cancer risk',\n opts: [\n 'HPV types 16 and 18 cause the large majority of cervical cancers and are classified as high-risk oncogenic types, whereas types 6 and 11 are low-risk types primarily responsible for genital warts rather than malignant transformation; vaccines target the high-risk oncogenic types driving cancer risk',\n 'HPV types 6 and 11 are the primary oncogenic drivers of cervical cancer, while types 16 and 18 are the low-risk types mainly responsible for genital warts, meaning vaccination programmes target 6 and 11 specifically to reduce cancer incidence overall',\n 'All HPV types carry a comparable risk of progression to cervical cancer, so the distinction between \"high-risk\" and \"low-risk\" types is not considered clinically meaningful, and vaccination targets the most common circulating types rather than those linked to malignancy',\n 'HPV types 16 and 18 are responsible for genital warts specifically, while a separate group of high-risk types unrelated to them drives the vast majority of cervical cancer cases, making 16 and 18 more clinically relevant to benign disease than to malignancy itself'\n ],\n exp: '<strong>HPV 16 and 18<\/strong> are the high-risk oncogenic types responsible for the large majority of cervical cancers, while <strong>HPV 6 and 11<\/strong> are low-risk types whose main clinical manifestation is genital warts, not malignancy — vaccines are specifically designed to target the oncogenic types to reduce cancer incidence. <br><br>Reversing this pairing — calling 6\/11 oncogenic and 16\/18 wart-causing — inverts the foundational typing fact. Treating all HPV types as <strong>equally risky<\/strong> erases a clinically essential distinction that underlies the entire rationale for risk stratification and vaccine design. And separating 16\/18 from cancer risk entirely, attributing cancer to an unrelated group of types, also misattributes the single most important fact in HPV oncology.',\n imgId: null\n },\n\n {\n id: 2,\n tag: 'Endometrial Cancer — Unopposed Oestrogen Risk Factors',\n stem: 'A 58-year-old, obese, nulliparous woman with a history of PCOS presents with postmenopausal bleeding. Which of her features specifically increases her risk of endometrial cancer, and through what shared mechanism?',\n correct: 'Obesity, nulliparity, and PCOS all increase endometrial cancer risk through a shared mechanism of unopposed oestrogen exposure — peripheral aromatization of androgens in adipose tissue, fewer progesterone-dominant pregnancy periods, and chronic anovulation respectively, leaving the endometrium without adequate progesterone opposition',\n opts: [\n 'Obesity, nulliparity, and PCOS all increase endometrial cancer risk through a shared mechanism of unopposed oestrogen exposure — peripheral aromatization of androgens in adipose tissue, fewer progesterone-dominant pregnancy periods, and chronic anovulation respectively, leaving the endometrium without adequate progesterone opposition',\n 'Obesity increases risk specifically through direct carcinogenic effects of adipose tissue on endometrial cells, unrelated to any hormonal mechanism, while nulliparity and PCOS are not considered meaningfully linked to endometrial cancer risk in current medical understanding of the disease',\n 'Nulliparity increases risk because pregnancy itself is directly protective through a mechanically distinct process from hormone exposure, while obesity and PCOS increase risk through entirely separate mechanisms involving insulin signalling rather than any shared oestrogen pathway',\n 'PCOS increases endometrial cancer risk specifically through chronically elevated progesterone levels from anovulatory cycles, a mechanism unrelated to the oestrogen-related pathways through which obesity and nulliparity are understood to increase risk overall'\n ],\n exp: 'All three risk factors converge on a single mechanism — <strong>unopposed oestrogen<\/strong>. In <strong>obesity<\/strong>, adipose tissue aromatises androgens into oestrogen peripherally; in <strong>nulliparity<\/strong>, the absence of pregnancy means fewer progesterone-dominant periods across a lifetime of cumulative cycling; in <strong>PCOS<\/strong>, chronic anovulation means no luteal phase progesterone to oppose oestrogen\\'s proliferative effect. <br><br>Obesity\\'s effect is hormonally mediated, not a direct, hormone-independent carcinogenic action. Pregnancy\\'s protection is itself a <strong>hormonal<\/strong> (progesterone-dominant) state, not a separate mechanical process. And anovulation in PCOS causes a <strong>lack<\/strong> of progesterone, not elevated progesterone — this last distractor inverts the actual hormonal direction entirely.',\n imgId: null\n },\n\n {\n id: 3,\n tag: 'Ovarian Cancer — Screening Limitations & CA-125',\n stem: 'A 45-year-old asymptomatic woman with no significant family history asks whether she should have an annual CA-125 blood test and pelvic ultrasound to screen for ovarian cancer. What is the appropriate response, and why?',\n correct: 'Routine screening with CA-125 and ultrasound is not recommended for an average-risk asymptomatic woman, since CA-125 lacks adequate sensitivity and specificity for screening, and no strategy has been shown to reduce ovarian cancer mortality in this population; screening is reserved for those at high genetic risk',\n opts: [\n 'Routine screening with CA-125 and ultrasound is not recommended for an average-risk asymptomatic woman, since CA-125 lacks adequate sensitivity and specificity for screening, and no strategy has been shown to reduce ovarian cancer mortality in this population; screening is reserved for those at high genetic risk',\n 'Annual CA-125 and ultrasound screening should be recommended for her, since this combination has been shown to reliably detect ovarian cancer at an early, more treatable stage in average-risk women and is the current standard of care for population-wide screening today',\n 'CA-125 alone, without ultrasound, is sufficient as an annual screening test for average-risk women, since CA-125 is highly specific for ovarian malignancy and a normal result reliably excludes early-stage disease in this population of women',\n 'Screening is unnecessary for her specifically because ovarian cancer is rare enough at age 45 that no screening strategy would be relevant until a substantially older age, even if a generally effective screening test for the disease did already exist'\n ],\n exp: 'No screening strategy — including <strong>CA-125 and ultrasound<\/strong> — has been shown to reduce ovarian cancer mortality in average-risk women; CA-125 is also <strong>non-specific<\/strong> (elevated in fibroids, endometriosis, and other benign conditions) and <strong>insensitive<\/strong> (many early cancers don\\'t raise it). Screening is reserved for those at high genetic risk (e.g. BRCA carriers). <br><br>Claiming this combination <strong>reliably detects<\/strong> early disease, or that CA-125 alone is <strong>highly specific<\/strong>, both overstate performance that large screening trials have failed to demonstrate. And while the conclusion to avoid screening is correct, attributing it to age-related <strong>rarity<\/strong> rather than the lack of an effective screening tool gets the actual reasoning wrong, even though it lands on the same recommendation.',\n imgId: null\n },\n\n {\n id: 4,\n tag: 'Staging Method — Cervical vs Endometrial & Ovarian Cancer',\n stem: 'How does the staging methodology for cervical cancer fundamentally differ from that used for endometrial and ovarian cancer?',\n correct: 'Cervical cancer is staged primarily using clinical assessment — examination, biopsy, and imaging — without requiring surgery to assign a stage, whereas endometrial and ovarian cancer are staged surgically, based on findings at laparotomy or laparoscopy including tissue sampling and assessment of spread',\n opts: [\n 'Cervical cancer is staged primarily using clinical assessment — examination, biopsy, and imaging — without requiring surgery to assign a stage, whereas endometrial and ovarian cancer are staged surgically, based on findings at laparotomy or laparoscopy including tissue sampling and assessment of spread',\n 'All three cancers — cervical, endometrial, and ovarian — use an identical surgical-pathological staging system, since FIGO staging methodology was deliberately standardised across all gynaecological malignancies to allow direct staging comparisons between them',\n 'Endometrial and ovarian cancer are staged clinically without surgery, similar to cervical cancer, since surgical staging was specifically discontinued for gynaecological malignancies in favour of imaging-based clinical assessment for all three cancers',\n 'Cervical cancer is staged surgically through laparotomy findings, while endometrial and ovarian cancer are staged clinically based on examination and imaging alone, the reverse of the actual methodological distinction between these cancer types'\n ],\n exp: '<strong>Cervical cancer<\/strong> is staged clinically — examination, biopsy, imaging — without requiring surgery, historically useful given its accessibility to direct examination and relevance in settings without surgical staging access. <strong>Endometrial and ovarian cancer<\/strong>, by contrast, require surgical-pathological staging — laparotomy or laparoscopy with tissue sampling and direct assessment of spread — because accurate staging depends on findings only surgery can provide. <br><br>Treating all three as using an <strong>identical system<\/strong>, or claiming endometrial\/ovarian cancer are staged <strong>clinically like cervical cancer<\/strong>, both erase this genuinely important methodological distinction. And simply <strong>reversing<\/strong> which cancer uses which method gets the direction backwards rather than the relationship itself.',\n imgId: null\n },\n\n {\n id: 5,\n tag: 'Postmenopausal Bleeding — Mandatory Endometrial Workup',\n stem: 'A 61-year-old presents with a single episode of light postmenopausal spotting. She is otherwise well, and the spotting has since stopped on its own. Should this be evaluated further, or can it reasonably be attributed to vaginal atrophy without investigation?',\n correct: 'Postmenopausal bleeding of any amount or duration, including a single light episode that has resolved, should be evaluated for endometrial cancer before being attributed to a benign cause, since endometrial cancer is the most common gynaecological malignancy presenting with postmenopausal bleeding and cannot be excluded by resolution alone',\n opts: [\n 'Postmenopausal bleeding of any amount or duration, including a single light episode that has resolved, should be evaluated for endometrial cancer before being attributed to a benign cause, since endometrial cancer is the most common gynaecological malignancy presenting with postmenopausal bleeding and cannot be excluded by resolution alone',\n 'Since the bleeding was light, brief, and has already resolved on its own, it can reasonably be attributed to vaginal atrophy without further evaluation, as self-limited postmenopausal spotting of this nature is not considered to warrant endometrial cancer workup at all',\n 'Evaluation is only necessary if the bleeding recurs or becomes heavier over time, since a single light episode that resolves spontaneously is generally considered low-risk enough to monitor expectantly before pursuing endometrial sampling or imaging in this case',\n 'Vaginal atrophy should be presumed as the cause and treated empirically with local oestrogen first, with endometrial evaluation reserved only for cases where bleeding persists despite treatment, given how common atrophy is as a cause of postmenopausal bleeding overall'\n ],\n exp: '<strong>Any postmenopausal bleeding<\/strong> — regardless of amount, duration, or whether it has resolved — warrants endometrial evaluation (sampling and\/or transvaginal ultrasound), because endometrial cancer is the most common gynaecological malignancy presenting this way and cannot be excluded on symptom characteristics alone. <br><br>Atrophy is indeed the most common overall <strong>cause<\/strong> of postmenopausal bleeding statistically, but that doesn\\'t license presuming it without first excluding cancer, given how serious a missed diagnosis would be. \"<strong>Waiting for recurrence<\/strong>\" and \"<strong>treating empirically first<\/strong>\" both delay the same necessary workup and share the same underlying error — assuming a benign cause before it has actually been confirmed.',\n imgId: null\n }\n\n ];\n\n var answers = {};\n var answered = 0;\n var shuffled = {};\n var done = false;\n\n function byId(id) { return document.getElementById(id); }\n function gid(suffix) { return byId(NS + '-' + suffix); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, tmp;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n tmp = a[i]; a[i] = a[j]; a[j] = tmp;\n }\n return a;\n }\n\n function countVal(val) {\n var k, n = 0;\n for (k in answers) {\n if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, imgDiv, imgSrc, j,\n optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n\n if (q.imgId) {\n imgSrc = byId(q.imgId);\n if (imgSrc) {\n imgDiv = document.createElement('div');\n imgDiv.innerHTML = imgSrc.innerHTML;\n expDiv.appendChild(imgDiv);\n }\n }\n\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = gid('pl' + qid);\n if (pl) pl.className = 'mr-pip-line done';\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#4B3A6E ' + disp + '%, #E0D8EC 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [\n [5, 'Clean sweep \\u2014 a strong close to the Gynaecology series.'],\n [4, 'Strong round \\u2014 one risk-mechanism or staging point to revisit.'],\n [3, 'Solid base \\u2014 the debrief will sharpen the screening-limitation and staging distinctions.'],\n [2, 'Halfway there \\u2014 review the missed cases carefully.'],\n [0, 'Gynaecological malignancies reward close re-reading \\u2014 the postmenopausal-bleeding rule is the one to watch.']\n ];\n gid('verdict').textContent = verdicts[4][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Gynaecological Malignancies Morning Rounds · Gynaecology Series · Round 07 GynaecologicalMalignancies Five cases · Cervical, endometrial & ovarian cancer · risk, screening & staging · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻ New Round<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,55],"tags":[82,93,83],"class_list":["post-37117","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-obg","tag-cms","tag-gynaecology","tag-neet-pg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gynaecological Malignancies - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gynaecological Malignancies - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Gynaecological Malignancies Morning Rounds · Gynaecology Series · Round 07 GynaecologicalMalignancies Five cases · Cervical, endometrial & ovarian cancer · risk, screening & staging · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻ New Round\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T00:32:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T00:33:36+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Gynaecological Malignancies\",\"datePublished\":\"2026-06-26T00:32:59+00:00\",\"dateModified\":\"2026-06-26T00:33:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/\"},\"wordCount\":47,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"CMS\",\"Gynaecology\",\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"OBG\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/\",\"name\":\"Gynaecological Malignancies - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-26T00:32:59+00:00\",\"dateModified\":\"2026-06-26T00:33:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/obg\\\/gynaecological-malignancies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gynaecological Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gynaecological Malignancies - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/","og_locale":"en_US","og_type":"article","og_title":"Gynaecological Malignancies - atsixty","og_description":"Morning Rounds \u00b7 Gynaecological Malignancies Morning Rounds · Gynaecology Series · Round 07 GynaecologicalMalignancies Five cases · Cervical, endometrial & ovarian cancer · risk, screening & staging · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief ↻ New Round","og_url":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/","og_site_name":"atsixty","article_published_time":"2026-06-26T00:32:59+00:00","article_modified_time":"2026-06-26T00:33:36+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Gynaecological Malignancies","datePublished":"2026-06-26T00:32:59+00:00","dateModified":"2026-06-26T00:33:36+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/"},"wordCount":47,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["CMS","Gynaecology","NEET-PG"],"articleSection":["Morning Rounds","OBG"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/","url":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/","name":"Gynaecological Malignancies - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-26T00:32:59+00:00","dateModified":"2026-06-26T00:33:36+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/obg\/gynaecological-malignancies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Gynaecological Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37117"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37117\/revisions"}],"predecessor-version":[{"id":37118,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37117\/revisions\/37118"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}